Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00004582 · ClinicalTrials.gov registry record · Phase 2

ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past

A Phase 2 study of HIV Infections, sponsored by ViRx.

Completed
Registry status
Phase 2
Development phase
1
Study location

NCT00004582: Completed Phase 2 study of HIV Infections, sponsored by ViRx.

NCT00004582 is a Phase 2 study of HIV Infections that has completed, run by ViRx. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00004582, a Phase 2 study of HIV Infections, has completed, sponsored by ViRx.

COMPLETED
Registry status
Phase 2
Development phase
1
Study location

Study Summary

The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).

Conditions Studied

HIV Infections

Interventions

  • DRUG Efavirenz
  • DRUG Lopinavir/Ritonavir

Study Locations (1)

California

  • ViRx Inc - San Francisco

Trial Details

FieldValue
Phase Phase 2
ViRx

1 total trials

What the finished NCT00004582 record still lists

NCT00004582 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Efavirenz is the first listed.

NCT00004582 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00004582 about?

NCT00004582 is a clinical study titled "ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past". The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).

What is the current status of trial NCT00004582?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00004582 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00004582?

The interventions under investigation include: Efavirenz (DRUG), Lopinavir/Ritonavir (DRUG).

Who is sponsoring clinical trial NCT00004582?

This trial is sponsored by ViRx, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00004582 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00004582, the US trial registry maintained by the National Library of Medicine. NCT00004582 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.